Phoenix Molecular Designs is Drug Discovery in Canada that focus on diagnostics target kinases business. Founded in 2012. They cover business area such as developer, cancer therapeutic platform, class, highly druggable enzyme, oncology indication, triple-negative breast cancer, medical professional, chemotherapy, hormone therapy, immunotherapy sensitization, refractory cancer.
2012
( 12 years old in 2024 )
Diagnostics Target Kinases
-
220-887 Great Northern Way
Vancouver, British Columbia V5T 4T5
Canada
Private
developercancer therapeutic platformclasshighly druggable enzymeoncology indicationtriple-negative breast cancermedical professionalchemotherapyhormone therapyimmunotherapy sensitizationrefractory cancer
* We use standard office opening hours in near Phoenix Molecular Designs's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Phoenix Molecular Designs is Drug Discovery business from Canada that founded in 2012 (12 years old in 2024), Phoenix Molecular Designs business is focusing on Diagnostics Target Kinases.
Phoenix Molecular Designs headquarter office and corporate office address is located in 220-887 Great Northern Way Vancouver, British Columbia V5T 4T5 Canada.
Phoenix Molecular Designs was founded in Canada.
In 2024, Phoenix Molecular Designs is currently focus on diagnostics target kinases sector.
Above is snippet of Google Trends for "diagnostics target kinases" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Phoenix Molecular Designs, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
